Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Onconetics Pharmaceuticals

Onconetics Pharmaceuticals?uq=8lCq2teR
2016 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Accelerator/Inc LATEST DEAL TYPE
$200K LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of a therapeutic platform created to facilitate personalized gene therapies for cancer. The company's platform utilizes a genetic switch which activates an apoptotic inducer to kill the cancer cell and spares healthy tissue, enabling physicians to target tumor cells with specific gene expression profiles.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Therapeutic Devices
Primary Office
  • San Francisco, CA
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Onconetics Pharmaceuticals’s full profile, request a free trial.

Onconetics Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 05-Oct-2017 $200K 00000 00.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Onconetics Pharmaceuticals Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
SOSV Venture Capital Minority 000 0000 000000 0

Onconetics Pharmaceuticals Executive Team (3)

Name Title Board
Seat
Contact
Info
Luke Gruenert Co-Founder, Chief Executive Officer & Board Member
Gabe Hitchcock Co-Founder, Chief Operating Officer & Board member
Geoffrey Sargent Ph.D Chief Scientific Officer

Onconetics Pharmaceuticals Board Members (2)

Name Representing Role Since Contact
Info
Gabe Hitchcock Onconetics Pharmaceuticals Co-Founder, Chief Operating Officer & Board member 000 0000
Luke Gruenert Onconetics Pharmaceuticals Co-Founder, Chief Executive Officer & Board Member 000 0000